Samyag

Corporate Actions

Back

Wockhardt surges after receiving US FDA approval for antibiotic drug Zaynich

01-Dec-25 13:28 Hrs IST

The aforementioned NDA was filed on 30 September 2025.

This is the first time in history that an NDA for a new chemical entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA,' the company said in a statement.

Zaynich has been granted 'fast track' designation by the US FDA, recognizing its potential to address urgent and unmet medical needs. As part of this pathway, the FDA has committed to assign priority to Zaynich NDA review.

Zaynich, a β-lactam enhancer, has drawn international interest for its activity against resistant gram-negative bacteria, which are linked to long hospital stays and high mortality. It has been used in critically ill patients in India and the United States.

Wockhardt is a global pharmaceutical and biotechnology company focused on developing anti-infective solutions.

The company had reported a consolidated net profit of Rs 78 crore in Q2 FY26 as against a net loss of Rs 22 crore recorded in Q2 FY25. Net sales declined 3.34% to Rs 782 crore in Q2 FY26 as compared with Q2 FY25.

Powered by Capital Market - Live News

Attention Investors: Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.|| KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.|| No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.